Asia Deal Watch: SciClone Obtains Commercial Rights In China To Menarini Breast Cancer Drug

20 Nov 2023

• By Vibha Ravi, Jung Won Shin, Lisa Takagi, Dexter Jie Yan, and Joseph Haas

Plus deals involving Fujimoto/Egetis, Chugai/Cheplapharm, Celest/Senti, Shionogi/Apnimed, Jiangsu Hengrui/Merck KGaA, Jiangsu Hengrui/Elevar, Sun/Zydus, C4U/Healiva, Shanghai Henlius/Intas, Ono/Turbine, EpimAB/Almirall and Alar/Indivior.

Asia Deal Watch: SciClone Obtains Commercial Rights In China To Menarini Breast Cancer Drug

More from Deal Watch

More from Deals